Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?

References

• Jennette JC, Falk R, Bacon P, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1-11.
   Google Scholar
• Devauchelle-Pensec V, Jousse S, Destombe C, et al. Epidemiology, imaging, and treatment of giant cell arteritis. Joint Bone Spine. 2008;75(3):267–272.
   PubMed Web of Science ®Google Scholar
• Warrington K, Matteson E. Management guidelines and outcome measures in giant cell arteritis (GCA). Clin Exp Rheumatol. 2007;25(6):S137.
   PubMed Web of Science ®Google Scholar
• De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42(1):119–125.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13(10):578.
   PubMed Web of Science ®Google Scholar
• Brack A, Martinez‐Taboada V, Stanson A, et al. Disease pattern in cranial and large‐vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–317.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Buttgereit F, et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology. 2017;56(4):506–515.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. Jama. 2016;315(22):2442–2458.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–245.
   PubMed Web of Science ®Google Scholar
• González‐Gay MA, Blanco R, Rodríguez‐Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–1504.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88(4):227–235.
   PubMed Web of Science ®Google Scholar
• Samson M, Jacquin A, Audia S, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg. 2015;86(2):216–221.
   PubMed Web of Science ®Google Scholar
• De Boysson H, Liozon E, Larivière D, et al. Giant cell arteritis–related stroke: a retrospective multicenter case-control study. J Rheumatol. 2017;44(3):297–303.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Wijarnpreecha K, Koster MJ, et al. Cerebrovascular accident in patients with giant cell arteritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2016;46(3):361–366.
   Google Scholar
• Pego-Reigosa R, Garcia-Porrua C, Pineiro A, et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol. 2004;22(Suppl 36):S13–S17.
   PubMedGoogle Scholar
• Graham E, Holland A, Avery A, et al. Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed). 1981;282(6260):269–271.
   PubMed Web of Science ®Google Scholar
• Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recent‐onset giant cell (temporal) arteritis: a case–control prospective study using helical aortic computed tomodensitometric scan. Arthritis Care Res. 2008;59(5):670–676.
   Web of Science ®Google Scholar
• Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170–1176.
   PubMed Web of Science ®Google Scholar
• Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med. 1995;122(7):502–507.
   PubMed Web of Science ®Google Scholar
• Liu G, Shupak R, Chiu BK. Aortic dissection in giant-cell arteritis. Semin Arthritis Rheum. 1995;25(3):160–171.
   Google Scholar
• Camellino D, Matteson EL, Buttgereit F, et al. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020;16(9):481–495.
   PubMed Web of Science ®Google Scholar
• Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc. 1957;163(10):821–827.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology. 2020;59(3):e1–e23.
   PubMed Web of Science ®Google Scholar
• Mainbourg S, Addario A, Samson M, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta‐analysis. Arthritis Care Res (Hoboken). 2020;72(6):838–849.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–323.
   PubMed Web of Science ®Google Scholar
• Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol. 1994;21(7):1283–1286.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Care Res. 2003;49(5):703–708.
   Web of Science ®Google Scholar
• De Silva M, Hazleman B. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–138.
   PubMed Web of Science ®Google Scholar
• Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S70–76.
   PubMed Web of Science ®Google Scholar
• Schaufelberger C, Möllby H, Uddhammar A, et al. No additional steroid‐sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35(4):327–329.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernández-García C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–114.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheumatism. 2002;46(5):1309–1318.
   PubMedGoogle Scholar
• Spiera R, Mitnick H, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–502.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta‐analysis. Arthritis Rheumatism. 2007;56(8):2789–2797.
   PubMed Web of Science ®Google Scholar
• Brouwer E, Van Der Geest KS, Sandovici M. Methotrexate in Giant Cell Arteritis Deserves a Second Chance—A High-dose Methotrexate Trial Is Needed.
   Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328.
   PubMed Web of Science ®Google Scholar
• Emilie D, Liozon E, Crevon M-C, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39(1):17–24.
   PubMed Web of Science ®Google Scholar
• Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin‐6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286–1294.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin‐6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43(5):1041–1048.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927.
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Dasgupta B, Luqmani R, et al. A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis. Rheumatol Ther. 2020;7(4):793–810.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–2081.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–630.
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada V, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–630.
   PubMed Web of Science ®Google Scholar
• Stone JH, Han J, Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3(5):e328–e336.
   Google Scholar
• Svasti-Salee CR, Mollan SP, Morgan AW, et al. Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Reports CP. 2019;12(10):e229236.
   PubMedGoogle Scholar
• Vionnet J, Buss G, Mayer C, et al. Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy. Joint Bone Spine. 2017;84(5):615–619.
   PubMed Web of Science ®Google Scholar
• Stone JH, Han J, Aringer M et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial Lancet Rheumatology. 2021;3(5):328–336.
   Google Scholar
• Koster MJ, Warrington KJ, Matteson EL. Morbidity and mortality of large-vessel vasculitides. Curr Rheumatol Rep. 2020;22(12):1–13.
   Web of Science ®Google Scholar
• Conway R, O’Neill L, McCarthy GM, et al. Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Ann Rheum Dis. 2018;77(12):1815–1824.
   PubMed Web of Science ®Google Scholar
• Espígol-Frigolé G, Planas-Rigol E, Lozano E, et al. Expression and function of IL12/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: contribution of p40 to Th1-and Th17-mediated inflammatory pathways. Front Immunol. 2018;9:809.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545.
   Google Scholar
• Conway R, O’Neill L, O’Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578–1579.
   PubMed Web of Science ®Google Scholar
• Matza MA, Fernandes AD, Stone JH, et al. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken). 2020.
   Web of Science ®Google Scholar
• Conway R, O’Neill L, Gallagher P, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial.
   Google Scholar
• Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):iii116–iii123.
   Google Scholar
• Ž R, Tomšič M, Hočevar A. Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. Rheumatology. 2018;57(5):934–936.
   PubMed Web of Science ®Google Scholar
• Sammut L, Litwic A, Smith R, et al. 002 Biopsy proven giant cell arteritis in a patient with psoriatic arthritis on TNF-alpha inhibitor treated with high dose prednisolone and a switch to secukinumab (anti IL-17). Rheumatology. 2018;57(suppl_3):key075. 226.
   Google Scholar
• Pountain G, Hazleman B, Cawston T. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol. 1998;37(7):797–798.
   PubMedGoogle Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology. 2004;43(3):294–301.
   PubMed Web of Science ®Google Scholar
• Ly K-H, Stirnemann J, Liozon E, et al. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81(1):76–78.
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, Double‐Blind trial of abatacept (CTLA‐4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837–845.
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double‐blind trial of abatacept (CTLA‐4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017;69(4):846–853.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cecchi I, Sciascia S, et al. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Clin Exp Rheumatol. 2021;39 Suppl 129:125–128.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(2):S121–S131.
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934–1948.
   PubMed Web of Science ®Google Scholar
• Pinet F. À quoi sert le système endothéline? What is the role of endothelin system? Med Sci (Paris). 2004;20:339–345.
   PubMedGoogle Scholar
• Pache M, Kaiser HJ, Haufschild T, et al. Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients. Am J Ophthalmol. 2002;133(1):160–162.
   PubMed Web of Science ®Google Scholar
• Lozano E, Segarra M, Corbera-Bellalta M, et al. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis. 2010;69(2):434–442.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112(6):1098–1103.
   PubMed Web of Science ®Google Scholar
• Cid MC, Gandhi R, Corbera-Bellalta M, et al. THU0008 GM-CSF pathway signature identified in temporal artery biopsies of patients with giant cell arteritis. Annals of the Rheumatic Diseases 2019;78:271–272.
   Google Scholar
• Terrier B, Geri G, Chaara W, et al. Interleukin‐21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheumatism. 2012;64(6):2001–2011.
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. 2019;50(4):796–811.
   PubMed Web of Science ®Google Scholar
• Cid MC, Ríos-Garcés R, Terrades-García N, et al. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. Rheumatology. 2020;59(Supplement_3):iii17–iii27.
   PubMedGoogle Scholar
• Minter R, Cohen E, Wang B, et al. Protein engineering and preclinical development of a GM‐CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol. 2013;168(1):200–211.
   PubMed Web of Science ®Google Scholar
• Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a fully human granulocyte–macrophage colony‐stimulating factor receptor α monoclonal antibody: long‐term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2018;70(5):679–689.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Zhang H, Maeda T, et al. GM-CSF is a pro-inflammatory cytokine in experimental vasculitis of medium and large arteries. Arthritis Rheumatol. 2019; 71 (suppl 10). [cited 2021 Jun 10]. Available from: https://acrabstracts.org/abstract/gm-csf-is-a-pro-inflammatory-cytokine-in-experimental-vasculitis-of-medium-and-large-arteries/
   Google Scholar
• Cid M, Unizony S, Pupim L, et al. Mavrilimumab (anti GM-CSF receptor α monoclonal antibody) reduces time to flare and increases sustained remission in a phase 2 trial of patients with giant cell Arteritis [abstract. Arthritis Rheumatol 72 (suppl). Arthritis Rheumatol. 2020;72.
   Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheumatism. 2011;63(3):633–639.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheumatism. 2003;48(12):3522–3531.
   PubMedGoogle Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheumatism. 2003;48(12):3532–3537.
   PubMedGoogle Scholar
• Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42(2):309–315.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheumatism. 2003;49(5):703–708.
   PubMed Web of Science ®Google Scholar